September 10, 2025Future Oncology

How I treat Ph+ acute lymphoblastic leukemia

View Full Paper

Ask AI

Bookmark

The introduction of ABL1 inhibitors has significantly improved survival in patients with Ph+ ALL, moving beyond traditional chemotherapy.
Imatinib, dasatinib, nilotinib, and ponatinib have changed treatment paradigms by combating resistance mutations in Ph+ ALL.
Blinatumomab offers a novel option, enabling some patients to avoid intensive chemotherapy and hematopoietic stem cell transplant.
Research continues to identify clinical and genetic features that predict relapse, further refining treatment strategies for Ph+ ALL.

Discussion

No takes yet. Share an insight, caveat, or question.

Review highlights advances in Ph+ ALL treatment, emphasizing ABL1 inhibitors, immunotherapy, and HSCT's evolving role.

Castro-Mollo et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark